MNCs acquiring Chinese biotech companies, but domestic big pharma may not follow suit.Investment focus shifting to non-oncology fields.Tofflon is in downward trend, not recommended for bottom-fishing
What is covered in the Full Insight:
Analyst Perspective on M&A transactions
Changing Investment Logic in Innovative Drugs
Analysis on Shanghai Tofflon Science A
Industry Viewpoints
Market Review and Risk Disclosure
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.